Vivani Medical Inc
NASDAQ:VANI
Net Margin
Vivani Medical Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Vivani Medical Inc
NASDAQ:VANI
|
59.8m USD | N/A | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
215.6B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.4B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
136.5B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
132.9B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.9B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.7B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.6B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
40.2B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.8B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
31.2B USD |
23%
|
Vivani Medical Inc
Glance View
Vivani Medical Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Emeryville, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Vivani Medical, Inc., formerly Second Sight Medical Products, Inc., is a developer of implantable visual prosthetics that creates an artificial form of useful vision for blind individuals. The firm is the combination of Nano Precision Medical, Inc. (NPM) and Second Sight Medical Products, Inc. NPM is a biopharmaceutical business that develops miniaturized, subdermal drug implants utilizing its NanoPortal technology to enable long-term, near constant-rate delivery of medicines to treat chronic diseases. Its divisions include Drug Implant & Visual Protheses division. The firm's Drug Implant division is developing a portfolio of miniature drug implants which utilize its NanoPortal drug implant technology. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. The firm's Visual Protheses division is developing implantable visual prostheses devices that are intended to deliver useful artificial vision to blind individuals.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Vivani Medical Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet